U.S. pharma huge copyright scrapped two experimental weight loss capsules previous calendar year—a once-everyday pill, lotiglipron, due to elevated liver enzymes plus a twice-day-to-day capsule, danuglipron, because of robust Unintended effects—but CEO Albert Bourla has mentioned the company is set to “Enjoy and earn” from the being overwei